Literature DB >> 8129633

Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data.

G V Sawle1, E D Playford, D J Burn, V J Cunningham, D J Brooks.   

Abstract

OBJECTIVE: To explore the relationship between normal and parkinsonian fluorodopa F 18 (18F-6-L-fluorodopa [18F-dopa]) uptake data to identify clinically normal subjects who may have preclinical Parkinson's disease.
DESIGN: A statistical comparison of striatal fluorodopa F 18 positron emission tomography scan data from patients with Parkinson's disease and normal controls.
SETTING: Positron emission tomography unit within a postgraduate teaching hospital. MAIN OUTCOME MEASURES: Discriminant function analysis used to compare the pattern of striatal (left and right caudate and putamen) fluorodopa F 18 uptake in normal subjects and patients with Parkinson's disease.
RESULTS: The discriminant score that best separates patients with Parkinson's disease from normal controls is a function of the lowest putamen influx constant minus a function of the caudate influx constant values. Borderline low normal subjects have slightly low fluorodopa F 18 uptake throughout the striatum, whereas patients with early Parkinson's disease have low fluorodopa F 18 uptake in one putamen with preserved uptake in the caudate (for normal subjects, subtracting the caudate influx constants from a function of the lowest putamen value lowers the discriminant score, although it remains positive; for patients, subtracting a larger caudate value from a function of the putamen uptake value leads to a negative score). One control subject had a borderline low discriminant score, compatible with focal nigral pathological changes as expected in preclinical Parkinson's disease. A repeated scan taken 3 years later showed a marked reduction in fluorodopa F 18 uptake, suggesting progressive nigral dysfunction.
CONCLUSION: Normal and parkinsonian fluorodopa F 18 uptake data differ both in the overall level of tracer uptake and in its spatial distribution. Subjects whose overall striatal fluorodopa F 18 uptake falls at the borderline of normal and parkinsonian values are likely to be normal if they have uniformly low uptake, but may have early or preclinical Parkinson's disease if uptake into putamen is very much lower than uptake into caudate.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8129633     DOI: 10.1001/archneur.1994.00540150027011

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  12 in total

Review 1.  Neuroimaging biomarkers for Parkinson disease: facts and fantasy.

Authors:  Joel S Perlmutter; Scott A Norris
Journal:  Ann Neurol       Date:  2014-11-07       Impact factor: 10.422

2.  Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort.

Authors:  Danna Jennings; Andrew Siderowf; Matthew Stern; John Seibyl; Shirley Eberly; David Oakes; Kenneth Marek
Journal:  JAMA Neurol       Date:  2017-08-01       Impact factor: 18.302

Review 3.  Progressive supranuclear palsy: clinical features, pathophysiology and management.

Authors:  A Rajput; A H Rajput
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging.

Authors:  M Hutchinson; U Raff
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

5.  Longitudinal trimodal imaging of midbrain-associated network degeneration in Parkinson's disease.

Authors:  Kenan Steidel; Marina C Ruppert; David J Pedrosa; Carsten Eggers; Andrea Greuel; Masoud Tahmasian; Franziska Maier; Jochen Hammes; Thilo van Eimeren; Lars Timmermann; Marc Tittgemeyer; Alexander Drzezga
Journal:  NPJ Parkinsons Dis       Date:  2022-06-22

6.  Onset pattern of nigrostriatal denervation in early Parkinson's disease.

Authors:  José A Pineda-Pardo; Álvaro Sánchez-Ferro; Mariana H G Monje; Nicola Pavese; José A Obeso
Journal:  Brain       Date:  2022-04-29       Impact factor: 15.255

7.  Clinical and [18F] dopa PET findings in early Parkinson's disease.

Authors:  P K Morrish; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-12       Impact factor: 10.154

8.  Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls.

Authors:  S A Eshuis; P L Jager; R P Maguire; S Jonkman; R A Dierckx; K L Leenders
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-27       Impact factor: 9.236

Review 9.  Neuroimaging in Parkinson disease: from research setting to clinical practice.

Authors:  Marios Politis
Journal:  Nat Rev Neurol       Date:  2014-11-11       Impact factor: 42.937

Review 10.  Positron emission tomography in the differential diagnosis of parkinsonism.

Authors:  Juha O Rinne
Journal:  J Mov Disord       Date:  2009-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.